Thomas Ichim

Thomas E.
Ichim founded Batu Biologics, Inc. in 2014, where he is working as President, Chief Executive Officer & Director from 2019, Tolerotech, Inc. in 2002, where he is working as Vice President-Business Development from 2002, MedVax Pharma Corp.
in 2003, where he worked as Chief Executive Officer from 2003 to 2005, Biorasi LLC in 2004, where he worked as Program Manager from 2004 to 2007, and Oncomune LLC in 2006, where he worked as Chief Technology Officer from 2006 to 2009.
Dr. Ichim also currently works at Therapeutic Solutions International, Inc., as Director from 2016, Creative Medical Health, Inc., as Director & President-Biotech Division from 2011, Creative Medical Technologies, Inc., as President & Director from 2016, Vendevia Group, as Managing Partner from 2004, Society of Clinical Research Associates, as Research Associate from 2005, and Immorta Bio, Inc., as Chief Scientific Officer & President.
Dr. Ichim also formerly worked at Emvolio, Inc., as Chief Executive Officer, Medistem, Inc., as President, Director & Chief Scientific Officer from 2013 to 2015, Regen Biopharma, Inc., as Director & Chief Scientific Officer from 2012 to 2015, Riordan Clinic Inc, as Director, Creative Medical Technology Holdings, Inc., as Director & Chief Scientific Officer from 2017 to 2021, Nobilis Therapeutics, Inc., as Director & Chief Scientific Officer, MarrowTech Pharma, Inc., as Director-Regulatory Affairs from 2000 to 2003, Carbon Manna UC, as Director from 2010 to 2011, Precigen, Inc., as Vice President-Cellular Therapies, and Batu Centre For Leukemia Research, as President from 1995 to 1997.
Dr. Ichim received his undergraduate degree in 1998 from The University of Waterloo, graduate degree in 2003 from the University of Western Ontario, and doctorate degree in 2007 from the University of Science, Arts & Technology.